



Fauzia Riaz, MD, MHS

Assistant Professor of Medicine (Oncology)

Medicine - Oncology

CLINICAL OFFICE (PRIMARY)

- **Stanford Women's Cancer Center**

900 Blake Wilbur Dr

1st Fl MC 5854

Palo Alto, CA 94304

Tel (650) 498-6004 **Fax** (650) 498-7237

Bio

BIO

Dr. Riaz is advancing biomarker-driven precision medicine in breast cancer through innovative clinical trials that integrate cutting-edge therapeutics and molecular insights.

Her research focuses on circulating tumor DNA (ctDNA) to detect minimal residual disease (MRD) in early-stage breast cancer, aiming to guide personalized treatment strategies. She is also developing novel approaches to enhance immunotherapy efficacy by modulating the tumor microenvironment, including early-phase trials that combine immunotherapy with radiotherapy. As an Assistant Professor at Stanford University School of Medicine, Dr. Riaz is committed to ensuring that these next-generation therapies are accessible to all patients..

CLINICAL FOCUS

- Breast Oncology
- Medical Oncology

ACADEMIC APPOINTMENTS

- Assistant Professor - University Medical Line, Medicine - Oncology

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Panel Member, National Comprehensive Cancer Network--Hematopoietic Growth Factors Panel (2020 - present)

PROFESSIONAL EDUCATION

- Board Certification: Medical Oncology, American Board of Internal Medicine (2019)
- Board Certification: Internal Medicine, American Board of Internal Medicine (2015)
- Fellowship: Yale Cancer Center (2019) CT
- Chief Residency, Georgetown University Medical Center , DC (2016)
- Residency: Georgetown University Medical Center (2016) DC

- Medical Education: University of South Florida Morsani College of Medicine (2012) FL

Research & Scholarship

CLINICAL TRIALS

- Phase III HER2/Neu Peptide GLSI-100 in HER2/Neu Positive & Residual Disease or High Risk PCR, Recruiting
- Expanded Access Pertuzumab & Trastuzumab Fixed-Dose Combo in HER2+ Breast Cancer During COVID-19 Pan, Not Recruiting
- Phase Ia/Ib LOXO-783 +/- Anticancer Tx in AdvancedBreastCancer &SolidTumors w/PIK3CA H1047R Mutation, Not Recruiting
- Phase III Dato-DXd vs Chemotherapy in Inoperable/Metastatic HR+ HER2- BreastCancer(TROPION-Breast01), Not Recruiting
- Phase III Ribociclib +Endocrine Therapy in Hormone Receptor-Positive HER2-Negative EarlyBreastCancer, Not Recruiting
- Phase III Sacituzumab Govitecan vs Physician's Choice Treatment in HR+/HER2-Metastatic BreastCancer, Not Recruiting
- Phase III TrastuzumabDeruxtecan vs Physician'sChoice in HER2LOW Unresectable/Metastatic BreastCancer, Not Recruiting

Publications

PUBLICATIONS

- **Impact of timing and breastfeeding on postpartum breast cancer diagnostic patterns and outcomes.** *Breast cancer research and treatment*
Klebaner, D., Park, N., Stone, K., Riaz, F., Crowe, S., Telli, M., Marquez, C., Horst, K.
2025
- **Impact of timing of diagnosis and breastfeeding on postpartum breast cancer outcomes.**
Klebaner, D., Park, N., Marquez, C., Stone, K., Crowe, S., Riaz, F., Telli, M. L., Horst, K. C.
LIPPINCOTT WILLIAMS & WILKINS.2025: e12537
- **New Treatment Approaches for Triple-Negative Breast Cancer.** *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting*
Riaz, F., Gruber, J. J., Telli, M. L.
2025; 45 (3): e481154
- **Association of driving distance to clinic with treatment route and dosing for metastatic breast cancer**
Riaz, F., Luo, I., Satoyoshi, M., Dalal, N., John, E. M., Schapira, L., Caswell-Jin, J., Kurian, A. W.
LIPPINCOTT WILLIAMS & WILKINS.2025: e13077
- **Cost and Cost-Effectiveness of Treating Human Epidermal Growth Factor Receptor 2-Low Metastatic Breast Cancer.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Dickerson, J. C., Moen, M. T., Nielsen, P., Riaz, F., Tran, E., Caswell-Jin, J. L., Suen, W., Goldhaber-Fiebert, J. D., Alarid-Escudero, F.
2025: JCO2401960
- **Patient-Centered Research Through Artificial Intelligence to Identify Priorities in Cancer Care.** *JAMA oncology*
Kim, J., Chen, M. L., Rezaei, S. J., Ramirez-Posada, M., Caswell-Jin, J. L., Kurian, A. W., Riaz, F., Sarin, K. Y., Tang, J. Y., Asch, S. M., Linos, E.
2025
- **Inpatient Immunotherapy Outcomes Study: A Multicenter Retrospective Analysis.** *JCO oncology practice*
Riaz, F., Vaughn, J. L., Zhu, H., Dickerson, J. C., Sayegh, H. E., Brongiel, S., Baldwin, E., Kier, M. W., Zaemes, J., Hearn, C., Abdelghany, O., Cohen, R. B., Parikh, et al
2025: OP2400788
- **New strategies for the management of triple-negative breast cancer.** *Current opinion in obstetrics & gynecology*
Riaz, F.
2024; 36 (1): 40-44
- **Pharmacovigilance Analysis of HeartFailure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer.** *JACC. CardioOncology*
Waliany, S., Caswell-Jin, J., Riaz, F., Myall, N., Zhu, H., Witteles, R. M., Neal, J. W.
2023; 5 (1): 85-98

- **The Inpatient Immunotherapy Outcomes study: A multicenter retrospective study of patients treated with immune checkpoint inhibitors in the inpatient setting**
Riaz, F., Zhu, H., Cheng, W., Brongiel, S., Baldwin, E., Kier, M., Zaemes, J., Hearn, C., Abdelghany, O., Parikh, R., Reuss, J. E., Prsic, E., Doroshow, et al
LIPPINCOTT WILLIAMS & WILKINS.2022: 300
- **Preliminary analysis of an expanded access study of the fixed-dose combination of pertuzumab (P) and trastuzumab (H) for subcutaneous injection (PH FDC SC) for at-home administration (admin) in patients (pts) with HER2-positive (HER2+) breast cancer (BC) during the COVID-19 pandemic.**
Dang, C. T., Tolaney, S. M., Riaz, F., Tan, A. R., Tkaczuk, K. H. R., Yu, A., Liu, J., Fung, A. M., Yang, A., Day, B., Rugo, H. S.
LIPPINCOTT WILLIAMS & WILKINS.2022
- **NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2022.** *Journal of the National Comprehensive Cancer Network : JNCCN*
Griffiths, E. A., Roy, V., Alwan, L., Bachiasvili, K., Baird, J., Cool, R., Dinner, S., Geyer, M., Glaspy, J., Gojo, I., Hicks, A., Kallam, A., Kidwai, et al
2022; 20 (5): 436-442
- **Uptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy Among Trial-Ineligible Patients With Advanced Solid Cancers.** *JAMA oncology*
Parikh, R. B., Min, E. J., Wileyto, E. P., Riaz, F., Gross, C. P., Cohen, R. B., Hubbard, R. A., Long, Q., Mamtani, R.
2021
- **Uptake and effectiveness of checkpoint inhibitor therapy among trial-ineligible patients with advanced solid malignancies.**
Parikh, R., Min, E., Wileyto, E., Riaz, F., Gross, C., Cohen, R. B., Hubbard, R. A., Long, Q., Mamtani, R.
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Adoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life.** *JCO oncology practice*
Riaz, F., Gan, G., Li, F., Davidoff, A. J., Adelson, K. B., Presley, C. J., Adamson, B. J., Shaw, P., Parikh, R. B., Mamtani, R., Gross, C. P.
2020: OP2000010
- **Uptake of first-line immune checkpoint inhibitors among medically frail patients with advanced solid malignancies.**
Parikh, R., Cohen, R. B., Min, E., Wileyto, E., Riaz, F., Gross, C., Long, Q., Mamtani, R.
LIPPINCOTT WILLIAMS & WILKINS.2020
- **The adoption of immune checkpoint inhibitors and patterns of care at the end of life.**
Riaz, F., Gan, G., Li, F., Davidoff, A. J., Adelson, K. B., Presley, C. J., Adamson, B. J. S., Shaw, P., Parikh, R., Mamtani, R., Gross, C.
AMER SOC CLINICAL ONCOLOGY.2020
- **Disparities in broad-based genomic sequencing for patients with advanced non-small cell lung cancer** *JOURNAL OF GERIATRIC ONCOLOGY*
Riaz, F., Presley, C. J., Chiang, A. C., Longtine, J. A., Soulos, P. R., Adelson, K. B., Herbst, R. S., Nussbaum, N. C., Sorg, R. A., Abernethy, A. P., Agarwala, V., Gross, C. P.
2019; 10 (4): 669-72